Profound Medical reports Q2 net loss of $15.7M; revenue flat at $2.2M; maintains 70-75% FY growth guidance

Profound Medical Corp.

2025-Q2 EPS reported $0.88 revenue$4,832,000

Net loss of $15.7M ($0.52/share) vs $6.9M ($0.28/share) in Q2 2024; revenue unchanged at $2.2M.
Gross margin improved to 73% from 64% on manufacturing efficiencies; operating expenses rose to $15.4M from $9.3M.
Same-store TULSA-PRO procedure volumes up 10% sequentially; pipeline of 80 new systems in qualifying stages.
CEO cites short-term capital sales delays but reaffirms FY 2025 revenue growth target of 70-75% YoY.
Cash position $35.2M; first commercial BPH treatment with TULSA-AI Volume Reduction Module conducted; full launch expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.